Skip to main content
Premium Trial:

Request an Annual Quote

IMDx to Develop Tests on Abbott's m2000 Platform

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IMDx reported on Thursday that it has entered into an agreement with Abbott to design, develop, and manufacture assays using Abbott's FDA-approved m2000 platform.

Privately held IMDx will also bring the assays through the regulatory process.

Financial and other terms of the multi-year deal were not disclosed.

The tests covered by the agreement include assays for Clostridium difficile, vancomycin-resistant Enterococci; Group B Streptococci; Influenza A/Influenza B, and Herpes simplex virus types 1 and 2. Two other tests, for determining the viral load for Epstein-Barr virus and for BK virus, will be commercialized outside the US, Cambridge, Mass.-based IMDx said.

The company uses its proprietary bioinformatics process to create its tests, ensuring products that are optimized and in silico verified, it said.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.